09:49 AM EST - ProMetic Life Sciences Inc. : Announced today that it has decided to close patient enrollment in its phase II open label study in patients suffering from type 2 diabetes and metabolic syndrome and will transition to a pivotal placebo-controlled phase II study in patients suffering from type 2 diabetes. ProMetic Life Sciences Inc.
shares T.PLI are trading down $0.12 at $3.42.
